Synthesis, binding, and modeling studies of new cytisine derivatives, as ligands for neuronal nicotinic acetylcholine receptor subtypes

Journal of Medicinal Chemistry

Volumn 52, Issue 14, 2009, Pages 4345-4357

  Tasso, Bruno ^a   Boido, Caterina Canu ^a   Terranova, Emanuela ^a   Gotti, Cecilia ^b,c   Riganti, Loredana ^b,c   Clementi, Francesco ^b,c   Artali, Roberto ^b   Bombieri, Gabriella ^b   Meneghetti, Fiorella ^b   Sparatore, Fabio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(CYTISIN 12 YL)ACETAMIDE; 1 (4 FLUOROPHENYL) 3 (CYTISIN 12 YL) 1 PROPANONE; 1 METHYL 4 (CYTISIN 12 YL) 1 BUTANONE; 1 PHENYL 2 (CYTISIN 12 YL) 1 ETHANONE; 1 PHENYL 3 (CYTISIN 12 YL) 1 PROPANONE; 1 PHENYL 4 (CYTISIN 12 YL) 1 BUTANONE; ALPHA BUNGAROTOXIN I 125; AMINO ACID; BINDING PROTEIN; BUNGAROTOXIN RECEPTOR; CYTISINE; CYTISINE DERIVATIVE; EPIBATIDINE H3; N (4 PHENYLBUTYL)CYTISINE DERIVATIVE; N [(PYRIDIN 3 YL)METHYL]CYTISINE DERIVATIVE; N [(PYRIDIN 4 YL)METHYL]CYTISINE DERIVATIVE; N [2 (4 FLUOROPHENYL)ETHYL]CYTISINE DERIVATIVE; N [2 (4 METHYLPHENYL)ETHYL]CYTISINE DERIVATIVE; N [2 (PYRIDIN 2 YL)ETHYL]CYTISINE DERIVATIVE; N [3 (4 FLUOROPHENYL)PROPYL]CYTISINE DERIVATIVE; N [3 (4 METHYLPHENYL)PROPYL]CYTISINE DERIVATIVE; N [3 (PYRIDIN 3 YL)PROPYL]CYTISINE DERIVATIVE; N [4 (4 FLUOROPHENYL)BUTYL]CYTISINE DERIVATIVE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NITROGEN; TEBANICLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALPHA CHAIN; ARTICLE; BETA CHAIN; BINDING SITE; CENTRAL NERVOUS SYSTEM; CORRELATION ANALYSIS; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HYDROPHOBICITY; LIGAND BINDING; LIPOPHILICITY; MOLECULAR DOCKING; MOLECULAR MODEL; MOLLUSC; NONHUMAN; QUANTUM MECHANICS; SUBSTITUTION REACTION;

ALKALOIDS; ANIMALS; AZOCINES; CELL LINE; HUMANS; LIGANDS; MODELS, MOLECULAR; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PROTEIN BINDING; PROTEIN CONFORMATION; QUINOLIZINES; RATS; RECEPTORS, NICOTINIC; THERMODYNAMICS;

EID: 67650756936     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900225j     Document Type: Article

References (90)

1. (a) Gotti, C.; Fornasari, D.; Clementi, F. Human neuronal nicotinic acetylcholine receptors. Prog. Neurobiol. 1997, 53, 199-237.
2. (b) Gotti, C.; Zoli, M.; Clementi, F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol. Sci. 2006, 27, 482-491.
3. Holladay, M. W.; Dart, M. J.; Lynch, J. K. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem. 1997, 40, 4169-4194.
4. Gotti, C.; Clementi, F. Neuronal nicotinic receptors: from structure to pathology. Prog. Neurobiol. 2004, 74, 363-396.
5. Cassels, B. K.; Bermúdez, I.; Dajas, F.; Abin-Carriquiry, J. A.; Wonnacott, S. From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research. Drug Discovery Today 2005, 10, 1657-1665.
6. Jensen, A. A.; Frolund, B.; Liljefors, T.; Krogsgaard-Larsen, P. Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and terapheutic inspirations. J. Med. Chem. 2005, 48, 4705-4745.
7. Lin, N.-H.; Meyer, M. D. Recent developments in neuronal nicotinic acetylcholine receptor modulators. Expert Opin. Ther. Patents 1998, 8, 991-1015.
8. Bunnelle, W. H.; Dart, M. J.; Schrimpf, M. R. Design of ligands for the nicotinic acetylcholine receptors: the quest for selectivity. Curr. Top. Med. Chem. 2004, 4, 299-334.
9. Glennon, R. A. Medicinal Chemistry of α4β2 nicotinic cholinergic receptor ligands. Prog. Med. Chem. 2004, 42, 55-123.
10. (a) Holladay, M. W.; Wasicak, J. T.; Lin, N. H.; Ne, Y.; Ryther, K. B.; Bannon, A. W.; Buckley, M. J.; Kim, D. J.; Decker, M. W.; Anderson, D. J.; Campbell, J. E.; Kuntzweiler, T. A.; Donnelly-Roberts, D. L.; Piattoni-Kaplan, M.; Briggs, C. A.; Williams, M.; Arneric, S. D. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2- chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. J. Med. Chem. 1998, 41, 407-412.
11. (b) Bannon, A. W.; Decker, M. W.; Holladay, M. W.; Curzon, P.; Donnelly-Roberts, D.; Puttfarcken, P. S.; Bitner, R. S.; Diaz, A.; Dickenson, A. H.; Porsolt, R. D.; Williams, M.; Arneric, S. P. Broad spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 1998, 279, 77-81.
12. (a) Arneric, S. P.; Sullivan, J. P.; Briggs, C. A.; Donnelly-Roberts, O.; Anderson, D. J.; Raszkiewicz, J. L.; Hughes, M. L.; Cadman, E. D.; Adams, P.; Garvey, D. S. (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT-418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization. J. Pharmacol. Exp. Ther. 1994, 270, 310-318.
13. (b) Decker, M. W.; Brioni, J. D.; Sullivan, J. P.; Buckley, M. J.; Radek, R. J.; Raszkiewicz, J. L.; Kang, C. H.; Kim, D. J.; Giardina, W. J.; Wasicak, J. T. (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT-418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J. Pharmacol. Exp. Ther. 1994, 270, 319-328.
14. 9-THC and other psychotogens. Life Sci. 1979, 25, 1043-1054.
15. (b) El-Seedi, H. R.; De Smet, P. A. G. M.; Beck, O.; Possnert, G.; Bruhn, J. G. J. Ethnopharmacol. 2005, 101, 238-242.
16. (a) Wonnacott, S. Brain nicotine binding sites. Hum. Toxicol. 1987, 6, 343-353.
17. 3H]-Cytisine binding to nicotine cholinergic receptors in brain. Mol. Pharmacol. 1991, 39, 9-12.
18. 3H]cytisine binding to human brain membrane preparations. Brain Res. 1993, 600, 127-133.
19. (a) Papke, R. L.; Heinemann, S. F. Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit. Mol. Pharmacol. 1994, 45, 142-149.
20. 7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 1997, 280, 346-356.
21. (c) Xiao, Y.; Kellar, K. J. The comparative pharmacology and up-regulation of rat neuronal nicotinic receptor subtype binding sites stably expressed in transfected mammaliam cells. J. Pharmacol. Exp. Ther. 2004, 310, 98-107.
22. Carbonnelle, E.; Sparatore, F.; Canu Boido, C.; Salvagno, C.; Baldani Guerra, B.; Terstappen, G.; Zwart, R.; Vijverberg, H.; Clementi, F.; Gotti, C. Nitrogen substitution modifies the activity of cytisine on neuronal nicotinic receptor subtypes. Eur. J. Pharmacol. 2003, 471, 85-96.
23. (a) Barlow, R. B.; McLeod, L. J. Some studies on cytisine and its methylated derivatives. Br. J. Pharmacol. 1969, 35, 161-174.
24. (b) Sloan, J. W.; Martin, W. R.; Bostwik, M.; Hook, R.; Wala, E. The comparative binding characteristics of nicotinic ligands and their pharmacology. Pharmacol., Biochem. Behav. 1988, 30, 255-267.
25. (c) Museo, E.; Wise, R. A. Cytisine induced behavioural activation: delineation of neuroanatomical locus of action. Brain Res. 1995, 670, 257-263.
26. (d) Rao, T. S.; Correa, L. D.; Reid, R. T.; Lloyd, G. K. Evaluation of antinociceptive effects of neuronal nicotinic acetylcholine receptors ligands in rat tail-flick assay. Neuropharmacology 1996, 35, 393-405.
27. (e) Seale, T. W.; Singh, R. S.; Basmadjian, G. Inherited selective hypoanalgesic response to cytisine in the tail-flick test in CF-1 mice. NeuroReport 1998, 9, 201-205.
28. (f) Ferger, B.; Spratt, C.; Teismann, P.; Seitz, K.; Kuschinsky, K. Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo. Eur. J. Pharmacol. 1998, 360, 155-163.
29. (a) Dallemagne, M. G.: Heymans, C. H. Respiratory stimulants. In Manske, R. H. F. Ed.; The Alkaloids, vol. 5; Academic Press: New York, 1955; pp 109-139.
30. (b) Zakusov, V. V. Farmacologiia, Medgiz: Moscow, 1960, p 203.
31. (a) Paun, D.; Franze, J. Raucherentwohnung mit cytisinhaltigen "Tabex" Tabletten. Dtsch. Gesundheitswes. 1968, 23, 2088-2091.
32. (b) Benndorf, S.; Kempe, G.; Scharfenberg, G.; Wendekamm, R.; Winkelvoss, E. Ergebnisse der medikamentosen Raucherentwohnung mit Cytisin (Tabex). Dtsch. Gesundheitswes. 1968, 23, 2092-2096.
33. (c) Seeger, R. Cytisin als Raucherentwohnungmittel? Med. Monatschr. Pharm. 1992, 15, 20-21.
34. (d) Etter, J.-F. Cytisine for smoking cessation. A literature review and a meta-analysis. Arch Intern. Med. 2006, 166, 1553-1559.
35. (e) Etter, J.-F.; Lukas, R. J.; Benowitz, N. L.; West, R.; Dresler, C. M. Cytisine for smoking cessation: A research agenda. Drug Alcohol Dep. 2008, 92, 3-8.
36. (a) Murakoshi, I.; Fuji, Y.; Takedo, S.; Arai, J. Lupin alkaloids as antidiabetics. Jpn. Kokai Tokkyo Koho, Japanese Patent 04-295480, 1992; Chem Abstr. 1993, 118, 45733.
37. (b) Murakoshi, I.; Fuji, Y.; Kawamura, H.; Marayama, H. Lupine alkaloids as antiinflammatory agents. Jpn. Kokai Tokkyo Koho, Japanese Patent 04-295479 (1992); Chem Abstr. 1993, 118, 45734
38. Lippiello, P. M.; Cladwell, W. S. Neurodegenerative diseases treatment with cytisine compounds (RJ Reynolds Tobacco Co.). U.S. Patent US 5,242,916, 1993; Chem. Abstr. 1993, 119, 217429
39. O'Neill, B. T. Preparation of pyridone-fused azabicyclic- or cytisine derivatives for use in addiction therapy. Patent PCT Int. Appl. WO98 1998, 18, 798, 1998; Chem. Abstr. 1998, 129, 4774
40. (a) Canu, C.; Sparatore, F. Cytisine derivatives as ligands for nicotinic receptor subtypes. Ital. Hung. Polish Joint Meet. on Med. Chem., Giardini Naxos, Sept 28-Oct 1, 1999. Abstracts book p 206.
41. (b) Canu Boido, C.; Sparatore, F. Synthesis and preliminary pharmacological evaluation of some cytisine derivatives. Farmaco 1999, 54, 438-451.
42. Nicolotti, O.; Canu Boido, C.; Sparatore, F.; Carotti, A. Cytisine derivatives as high affinity nAChR ligands: synthesis and comparative molecular field analysis. Farmaco 2002, 57, 469-478.
43. Canu Boido, C.; Tasso, B.; Boido, V.; Sparatore, F. Cytisine derivatives as ligands for neuronal nicotinic receptors and with various pharmacological activities. Farmaco 2003, 58, 265-277.
44. Riganti, L.; Matteoni, C.; Di Angelantonio, S.; Nistri, A.; Gaimarri, A.; Sparatore, F.; Canu Boido, C.; Clementi, F.; Gotti, C. Long-term exposure to the new nicotinic antagonist 1,2-bis-N-cytisinylethane upregulates nicotinic receptor subtypes of SH-SY5Y human neuroblastoma cells. Br. J. Pharmacol. 2005, 146, 1096-1109.
45. (a) Imming, P.; Klaperski, P.; Stubbs, M. T.; Seitz, G.; Gundisch, D. Syntheses and evaluation of halogenated cytisine derivatives and of bioisosteric thiocytisine as potent and selective nAChR ligands. Eur. J. Med. Chem. 2001, 36, 375-388.
46. (b) Fitch, R. W.; Kaneko, Y.; Klaperski, P.; Daly, J. W.; Seitz, G.; Gundisch, D. Halogenated and isosteric cytisine derivatives with increased affinity and functional activity at nicotinic acetylcholine receptors. Bioorg. Med. Chem. Lett. 2005, 15, 1221-1224.
47. 4 nicotinic acetylcholine receptors. J. Neurochem. 2001, 78, 1029-1043.
48. (b) Slater, Y. E.; Houlihan, L. M.; Maskell, P. D.; Exley, R.; Bermúdez, I.; Lukas, R. J.; Valdivia, A. C.; Cassels, B. K. Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology 2003, 44, 503-515.
49. (c) Abin-Carriquiry, J. A.; Voutilainen, M. H.; Barik, J.; Cassels, B. K.; Iturriaga-Vásquez, P.; Bermúdez, I.; Durand, C.; Dajas, F.; Wonnacott, S. C3-halogenation of cytisine generates potent and efficacious nicotinic receptor agonists. Eur. J. Pharmacol. 2006, 536, 1-11.
50. (d) Abin-Carriquiry, J. A.; Costa, G.; Urbanavicius, J.; Cassels, B. K.; Rebolledo-Fuentes, M.; Wonnacott, S.; Dojes, F. In vivo modulation of dopaminergic nigrostriatal pathways by cytisine derivatives: Implications for Parkinson's Disease. Eur. J. Pharmacol. 2008, 589, 80-84.
51. (a) Marrière, E.; Rouden, J.; Tadino, V.; Lasne, M.-C. Synthesis of analogues of (-)-cytisine for in vivo studies of nicotinic receptors using positron emission tomography. Org. Lett. 2000, 2, 1121-1124.
52. 2 receptor imaging with PET. Bioorg. Med. Chem. 2003, 11, 5333-5343.
53. (c) Chellappan, S. K.; Xiao, Y.; Tueckmontel, W.; Kellar, K. J.; Kozikowski, A. P. Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity. J. Med. Chem. 2006, 49, 2673-2676.
54. 2 nicotinic acetylcholine receptors. ChemMedChem 2007, 2, 1157-1161.
55. (a) Rouden, J.; Ragot, A.; Gouault, S.; Cahard, D.; Plaquevent, J.-C.; Lasne, M.-C. Regio- and diastereoselective functionalization of (-)-cytisine: an unusual N-C acyl migration. Tetrahedron: Asymmetry 2002, 13, 1299-1305.
56. (b) Houllier, N.; Gouault, S.; Lasne, M.-C.; Rouden, J. Regio and diastereoselective functionalization of (-)-cytisine. Tetrahedron 2006, 62, 11679-11686.
57. (a) Kozikowski, A. P.; Musachio, J. L.; Kellar, K. J.; Xiao,Y.; Wei, Z.-L. Ligands for nicotinic acetylcholine receptors, and methods of making and using them. Patent PCT WO2005/000806 A2, 2005.
58. (b) Tilotta, M. C. Novel nicotinic acetylcholine receptor ligands based on cytisine, ferruginine, anatoxin-a and choline: in vitro evaluation and structure-activity relationships. http://hss.ulb.unibonn.de/diss-online/ math-nat-fak/2004/tilotta-maria/0464.pdf.December2, 2005.
59. (a) Rakhimov, Sh.B.; Vinogradova, V. J.; Mirzaev, Y. R.; Vyrova, N. L.; Kuzantseva, D. S. Synthesis and biological activity of N-benzyl derivatives of cytisine. Chem. Nat. Compd. 2006, 42, 462-469.
60. (b) Safrykine, V. A.; Vinogradova, V. J.; Ambartsumova, R. F.; Ibragimov, T. F.; Shakhidoyatov, K. M. Thiazole and benzothiazole derivatives of cytisine. Chem. Nat. Compd. 2006, 42, 470-472.
61. (c) Frasinyak, M. S.; Turov, A. V.; Vinogradova, V. I.; Khilya, V. P. Aminomethylation of cytisine by 3-hetaryl-7-hydroxychromones. Chem. Nat. Compd. 2007, 43, 285-290.
62. (d) Nizri, E.; Irony-Tur-Sinai, M.; Lavon, I.; Meshulam, H.; Amitai, G.; Brenner, T. IBU-Octyl-cytisine, a novel bifunctional compound eliciting anti-inflammatory and cholinergic activity, ameliorates CNS inflammation by inhibition of T-cell activity. Int. Immunopharm. 2007, 7, 1129-1139.
63. 2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 2005, 48, 3474-3477.
64. 2 nicotinic partial agonists for smoking cessation: carbon analogs of (-)-cytisine. Bioorg. Med. Chem. Lett. 2005, 15, 2974-2979.
65. 2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg. Med. Chem. Lett. 2005, 15, 4889-4897.
66. 2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 12518-12523.
67. (e) Eisenberg, M. J.; Filion, K. B.; Yavin, D.; Bélisle, P.; Mottillo, S.; Joseph, B.; Gervais, A.; O'Loughlin, J.; Paradis, G.; Rinfret, S.; Pilote, L. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAY 2008, 179, 135-144.
68. (a) Brejc, K.; van Dijk, W. J.; Klaassen, R. V.; Schuurmans, M.; van der Oost, J.; Smit, A. B.; Sixma, T. K. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 2001, 411, 269-276.
69. (b) Unwin, N. Refined structure of the nicotinic acetylcholine receptor at 4 Å resolution. J. Mol. Biol. 2005, 346, 967-989.
70. +2 binding sites. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 3210-3215.
71. Bourne, Y.; Talley, T. T.; Hansen, S. B.; Taylor, P.; Marchot, P. Crystal structure of a Cbtx-AchBP complex reveals essential interactions between snake alpha-neurotoxins and nicotinic receptors. EMBO J. 2005, 24, 1512-1522.
72. Bombieri, G.; Meneghetti, F.; Artali, R.; Tasso, B.; Canu Boido, C.; Sparatore, F. The influence of the nitrogen substitution in three cytisine derivatives as ligands for the neuronal nAChRs: a structural and theoretical study. Chem. Biodiversity 2008, 5, 1867-1878.
73. Artali, R.; Bombieri, G.; Meneghetti, F. Docking of 6-chloropyridazin-3- yl derivatives active on nicotinic acetylcholine receptors into molluscan acetylcholine binding protein (AChBP). Farmaco 2005, 60, 313-320.
74. (a) Dwoskin, L. P.; Xu, R.; Ayers, J. T.; Crooks, P. A. Recent developments in neuronal nicotinic acetylcholine receptor antagonists. Expert Opin. Ther. Patents 2000, 10, 1561-1581.
75. (b) Dwoskin, L. P.; Crooks, P. A. Competitive neuronal nicotinic receptor antagonists: a new direction for drug discovery. J. Pharmacol. Exp. Ther. 2001, 298, 395-402.
76. Fabio, P. F.; Lang, S. A.; Lin, Y.-I; Tomcufcik, A. S. Antiamebic amidines and sulfonamides of 5- and 6-amino-2,3-bis(4-alkyl-1-piperazinyl) quinoxalines. J. Med. Chem. 1980, 23, 201-206.
77. Bixler, L. B.; Nieman, C. Synthesis of b-(4-pyridyl)-DL-alanine and of b-(4-pyridyl-1-oxide)-DL, D- and L-alanine. J. Org. Chem. 1958, 23, 575-584.
78. Coombes, R. G.; Johnson, H. D.; Winterton,N. s-Bonded organotransition-metal ions. Part I. The formation of air-stable penta-aquopyridiomethylchromium (III) ions. J. Chem. Soc. 1965, 7029-7035.
79. Takamatsu, S; Saito, K; Ohmiya, S.; Ruangrangsi, N.; Murakoshi, I. Lupin alkaloids from Sophora exigua. Phytochemistry 1991, 30, 3793-3795.
80. Balestra, B.; Moretti, M.; Longhi, R.; Mantegazza, R.; Clementi, F.; Gotti, C. Antibodies against neuronal nicotinic receptor subtypes in neurological disorders. J. Neuroimmunol. 2000, 102, 89-97.
81. Munson, P. J.; Rodbard, D. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 1980, 107, 220-239.
82. Ghemical molecular modelling package. [http://www.bioinformatics.org/ ghemical.
83. (a) Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated Docking Using a Lamarckian Genetic Algorithm and Empirical Binding Free Energy Function. J. Comput. Chem. 1998, 19, 1639-1662.
84. (b) Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. A Semiempirical Free Energy Force Field with Charge-Based Desolvation. J. Comput. Chem. 2007, 28, 1145-1152.
85. (a) Hetényi, C.; van der Spoel, D. Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci. 2002, 11, 1729-1737.
86. (b) Hetényi, C.; van der Spoel, D. Blind docking of drug-sized compounds to proteins with up to a thousand residues. FEBS Lett. 2006, 580, 1447-1450.
87. Miyamoto, S.; Kollman, P. A. SETTLE - an analytical version of the shake and rattle algorithm for rigid water models. J. Comput. Chem. 1992, 13, 952-962.
88. Hess, B.; Bekker, H.; Berendsen, H. J. C.; Fraaije, J. G. E. M. LINCS: a linear constraint solver for molecular simulations, J. Comput. Chem., 1997, 18, 1463-1472.
89. Collaborative Computational Project, Number 4. The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr., Sect. D: Biol Crystallogr. 1994, 50, 760-763.
90. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, J. A., Jr.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A.; Gaussian 03, revision A.1; Gaussian: Pittsburgh, PA, 2003.